Eli Lilly and Incyte announces positive results of two phase 3 clinical trials investigating the use of JAK inhibitor baricitinib as both a monotherapy and combination therapy for moderate-to-severe atopic dermatitis.
Menlo and Foamix announces shareholders have voted to approve the proposed merger between the two companies. Anticipated finalization of the merger is March 2020.
Sol-Gel announces updates to their drug pipeline and their goals for 2020, which include submitting multiple provisional patents and NDAs for the treatment of a variety of skin conditions.
Dr. Brian Biesman sits down with Dermatology Times to talk about the important role surgery plays in eyelid rejuvenation.
The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.
Medical device company Soliton presents results from their 12-week study looking at the treatment of fibrotic scars via their RAP device at Maui Derm.
Hovione recently published results of a phase 2b study showed a topical gel formulation of 1% and 3% minocycline proved to be an effective and safe treatment for papulopustular rosacea.
South Florida practitioner Dr. Susan Weinkle received the JDD Outstanding Educator & Mentor in Dermatology at the ODAC held Jan.17-20 in Orlando, Fla. The award recognizes continuing contributions to the dermatology industry through education.
Crown Laboratories has announced business division restructuring to establish themselves in the global skin care and dermatology market.
Medical device company, Soliton will present results from their 12-week study looking at the treatment of fibrotic scars using their RAP device at Maui Derm Jan. 25-29.